Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Med Chem Group supports the CMD Pillars to select druggable targets, and discover and optimise small molecule leads.

Med Chem Methods

Target Assessment

In collaboration with Research Informatics

Target DB

TargetDB is a rapid, easy to interpret, target assessment tool. 

 

Fragment-based Drug Discovery

In collaboration with Protein Crystallography

Poised Frag

Poised Fragments allow rapid chemistry expansion of fragment hits. 

 

Structure- and Ligand-Based Drug Design

HCIE

The HeteroCycle Isostere Explorer (HCIE) finds novel scaffolds based on shape and electrostatic similarity.

 

Organic Synthesis

Org Syn

Where are your gloves Moses?

 

Drug Discovery projects

Neurodegeneration

With the Alzheimer's Research UK Oxford Drug Discovery Institute

USP30.jpeg

 USP30 inhibitors increase mitophagy to treat Parkinson's Disease.

Rare Diseases

Ataxias

FASUV420H.jpeg 

SUV420H1/2 inhibitors increase Frataxin levels to treat Friedreich's Ataxia.

Oncology

Epigenetics and Epitranscriptomics

KDM5 v2

Covalent inhibitors are selective for KDM5.

 

Anti-infectives

NSP3 Macro

Medium throughput screening identified inhibitors of the SARS-CoV-2 NSP3 macro domain. 

Our team

Selected publications